comparemela.com

Page 4 - C Difficile News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Lumen Bioscience awarded $16 2 million to advance C difficile treatment

Lumen Bioscience has been granted $16.2 million by the U.S. Department of Defense to advance its C. difficile infection (CDI) treatment.

Carl masonLumen bioBio developmentsMarkets amp regulationsC difficileFood and drug administrationLumen bioscience

Calprotectin, Microbiota Levels Can Predict C Diff Recurrence, Study Finds

Age, fecal calprotectin level, toxin B polymerase chain reaction cycle threshold, immunosuppression, sex, and creatinine levels were identified as independent risk factors for developing recurrent Clostridioides difficile (C Diff) infection.

United statesGregorio maraUniversitario gregorio maraHealth research instituteHospital general universitario gregorio maraC difficileInfectious diseaseNonrecurrent disease

Asymptomatic C difficile Screening During ICU Admissions Reveals Greater Infection Risk

Clostridioides difficile (C difficile) screening in all ICU admissions identified asymptomatic carriers and their risk for developing and/or transmitting infection.

United statesContagion liveC difficileInfectious disease

C difficile, COVID-19 Coinfection Risk Greatest in Older Women

Those with certain comorbidities, including peptic ulcer disease and renal failure, were at additional risk of developing Clostridioides difficile infection.

Kalvin yuNational inpatient sampleUniversity of missouri school medicineXheni dedaMissouri schoolC difficileCovid 19Infectious diseaseOlder womenClostridioides difficile

Hospital-Onset C Diff Not Linked to Cross-Transmission

Findings showed colonization with toxigenic C. difficile was associated with a greater risk of CDI during hospitalization than cross-transmission.

United statesEvan snitkinUniversity of michigan medical schoolUs centers for diseaseCenters for diseaseRush university medical centerMichigan medicineMichigan medicalDisease controlPublished septemberAccessed septemberC diffC difficileClostridioides difficile

vimarsana © 2020. All Rights Reserved.